Prognosis markers for metastatic renal cell carcinoma: quantitative proteomics approach

References

• Figlin RA. Renal cell carcinoma: management of advanced disease. J. Urol. 161(2), 381–6; discussion 386 (1999).
   PubMed Web of Science ®Google Scholar
• Steinbach F, Stöckle M, Kiewel R, Störkel S, Stein R, Hohenfellner R. Prognostic parameters of renal cell carcinoma. Clinicopathologic and DNA image cytometric analysis in 133 pT3a cases. Eur. Urol. 24(2), 279–285 (1993).
   Google Scholar
• Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J. Clin. 48(1), 6–29 (1998).
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J. Clin. 53(1), 5–26 (2003).
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J. Urol. 166(5), 1611–1623 (2001).
   PubMed Web of Science ®Google Scholar
• Russo P. Renal cell carcinoma: presentation, staging, and surgical treatment. Semin. Oncol. 27(2), 160–176 (2000).
   PubMed Web of Science ®Google Scholar
• Bukowski RM, Novick AC. Clinical practice guidelines: renal cell carcinoma. Cleve. Clin. J. Med. 64(Suppl. 1), SI1–44; quiz SI45 (1997).
   Google Scholar
• Chang AE, Aruga A, Cameron MJ et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J. Clin. Oncol. 15(2), 796–807 (1997).
   PubMed Web of Science ®Google Scholar
• Gitlitz BJ, Belldegrun A, Figlin RA. Immunotherapy and gene therapy. Semin. Urol. Oncol. 14(4), 237–243 (1996).
   Google Scholar
• Gross AJ, Michl UH, Bornhöft G, Dieckmann KP. Neuron-specific enolase: a serum tumor marker in renal cell carcinoma? Eur. Urol. 24(3), 397–399 (1993).
   Google Scholar
• Junker U, Knoefel B, Nuske K et al. Transforming growth factor beta 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma. Cytokine 8(10), 794–798 (1996).
   PubMedGoogle Scholar
• Partin AW, Criley SR, Steiner MS et al. Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor volume. Urology 45(2), 211–217 (1995).
   Google Scholar
• Bissig H, Richter J, Desper R et al. Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization. Am. J. Pathol. 155(1), 267–274 (1999).
   PubMed Web of Science ®Google Scholar
• Kuukasjärvi T, Karhu R, Tanner M et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 57(8), 1597–1604 (1997).
   PubMed Web of Science ®Google Scholar
• Nguyen DX, Massagué J. Genetic determinants of cancer metastasis. Nat. Rev. Genet. 8(5), 341–352 (2007).
   PubMed Web of Science ®Google Scholar
• Celis A, Rasmussen HH, Celis P et al. Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities. Electrophoresis 20(2), 355–361 (1999).
   PubMed Web of Science ®Google Scholar
• Sarto C, Marocchi A, Sanchez JC et al. Renal cell carcinoma and normal kidney protein expression. Electrophoresis 18(3-4), 599–604 (1997).
   PubMedGoogle Scholar
• Unwin RD, Craven RA, Harnden P et al. Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 3(8), 1620–1632 (2003).
   PubMed Web of Science ®Google Scholar
• Sarto C, Déon C, Doro G, Hochstrasser DF, Mocarelli P, Sanchez JC. Contribution of proteomics to the molecular analysis of renal cell carcinoma with an emphasis on manganese superoxide dismutase. Proteomics 1(10), 1288–1294 (2001).
   PubMedGoogle Scholar
• Masui O, White NM, Desouza LV et al. Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance. Mol. Cell Proteomics 12(1), 132–144 (2012).
   Google Scholar
• Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med. 49(Suppl. 2), 24S–42S (2008).
   PubMed Web of Science ®Google Scholar
• Huang SK, Darfler MM, Nicholl MB et al. LC/MS-based quantitative proteomic analysis of paraffin-embedded archival melanomas reveals potential proteomic biomarkers associated with metastasis. PLoS ONE 4(2), e4430 (2009).
   PubMed Web of Science ®Google Scholar
• Wang Y, Lin L, Zheng C. Downregulation of Orai1 expression in the airway alleviates murine allergic rhinitis. Exp. Mol. Med. 44(3), 177–190 (2012).
   PubMedGoogle Scholar
• Yang LP, Jiang S, Liu JQ, Miao XY, Yang ZL. Association of immunostaining of galectin-3 and Sambucus nigra agglutinin with invasion, metastasis and poor progression of gallbladder adenocarcinoma. Hepatogastroenterology 59(119), (2012).
   Google Scholar
• Bürger A, Filsinger S, Cooper DN, Hänsch GM. Expression of the 14 kDa galactose-binding protein, galectin-1, on human tubular epithelial cells. Kidney Int. 50(3), 754–759 (1996).
   Google Scholar
• Saussez S, Nonclercq D, Laurent G et al. Toward functional glycomics by localization of tissue lectins: immunohistochemical galectin fingerprinting during diethylstilbestrol-induced kidney tumorigenesis in male Syrian hamster. Histochem. Cell Biol. 123(1), 29–41 (2005).
   Google Scholar
• Danguy A, Camby I, Kiss R. Galectins and cancer. Biochim. Biophys. Acta 1572(2-3), 285–293 (2002).
   PubMed Web of Science ®Google Scholar
• Perillo NL, Pace KE, Seilhamer JJ, Baum LG. Apoptosis of T cells mediated by galectin-1. Nature 378(6558), 736–739 (1995).
   PubMed Web of Science ®Google Scholar
• Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87(4), 619–628 (1996).
   PubMed Web of Science ®Google Scholar
• Neal CL, Yao J, Yang W et al. 14-3-3ζ overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res. 69(8), 3425–3432 (2009).
   PubMed Web of Science ®Google Scholar
• Zang L, Palmer Toy D, Hancock WS, Sgroi DC, Karger BL. Proteomic analysis of ductal carcinoma of the breast using laser capture microdissection, LC-MS, and 16O/18O isotopic labeling. J. Proteome Res. 3(3), 604–612 (2004).
   PubMed Web of Science ®Google Scholar